Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.39 |
| ▸ | TK2 | O00142 | 1/20 | 0.38 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11205602 | 0.89 | TK1 (0.57) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL11205610 | 0.89 | TK1 (0.57) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL9470943 | 0.85 | LMNA (0.53) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL9443821 | 0.85 | RNASE1 (0.48) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL21563855 | 0.85 | RNASE1 (0.48) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL9470932 | 0.85 | LMNA (0.53) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL537189 | 0.85 | RNASE1 (0.48) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL4728022 | 0.85 | TK1 (0.53) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL2922542 | 0.84 | TK1 (0.42) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL779334 | 0.84 | TK1 (0.42) | TK1CYP1A2CYP3A4TSHRBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0573479-A1 | CHIMERIC TAR ENZYME CONSTRUCTION FOR HIV THERAPY | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-12-15 | — | — | EP | claimed |
| WO-1992015693-A1 | CHIMERIC TAR ENZYME CONSTRUCTION FOR HIV THERAPY | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-09-17 | — | — | WO | claimed |
| US-6699690-B2 | LINKED AND CONTROLLING THE EXPRESSION OF A HETEROLOGOUS ENZYME, FOR EXAMPLE VARICELLA ZOSTER VIRUS THYMIDINE KINASE OR NON-MAMMALIAM CYTOSINE DEAMINASE | SMITHKLINE BEECHAM CORPORATION | 2004-03-02 | — | — | US | disclosed |
| US-20020055482-A1 | Linked and controlling the expression of a heterologous enzyme, for example Varicella Zoster Virus Thymidine Kinase or non-mammaliam Cytosine Deaminase | SMITHKLINE BEECHAM CORPORATION | 2002-05-09 | — | — | US | disclosed |
| US-6337209-B1 | A CHIMERIC MOLECULE; THERAPY FOR COLORECTAL CANCER | GLAXO WELLCOME INC. | 2002-01-08 | — | — | US | disclosed |
| US-6300490-B1 | EXPRESSION VECTOR CODING CYTOSINE DEAMINASE; FOR USE IN THE TREATMENT OF CANCERS | GLAXO WELLCOME INC. | 2001-10-09 | — | — | US | disclosed |
| EP-0573479-A1 | CHIMERIC TAR ENZYME CONSTRUCTION FOR HIV THERAPY | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-12-15 | — | — | EP | disclosed |
| WO-1992015693-A1 | CHIMERIC TAR ENZYME CONSTRUCTION FOR HIV THERAPY | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-09-17 | — | — | WO | disclosed |
| EP-0486477-A2 | 1-( -D-Arabinofuranosyl)-5-propynyluracil as a VZV-antiviral compound | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-05-20 | — | — | EP | disclosed |
| US-5079235-A | 5-Substituted Pyrimidine Nucleosides | BURROUGHS WELLCOME CO. (US) | 1992-01-07 | — | — | US | disclosed |
| EP-0272065-A2 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055482-A1 | Linked and controlling the expression of a heterologous enzyme, for example Varicella Zoster Virus Thymidine Kinase or non-mammaliam Cytosine Deaminase | TK1, CDA, DCTD | TK1 1/4885CYP1A2 2352/4885CYP3A4 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.